about
Models for Predicting Drug Absorption From Oral Lipid-Based FormulationsSurface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and UsesPharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulationsA simple quantitative approach for the determination of long and medium chain lipids in bio-relevant matrices by high performance liquid chromatography with refractive index detection.Preparation, characterization, and evaluation of dipfluzine-benzoic acid co-crystals with improved physicochemical properties.Acyclic CB[n]-type molecular containers: effect of solubilizing group on their function as solubilizing excipients.Acyclic Cucurbit[n]uril-Type Molecular Containers: Influence of Linker Length on Their Function as Solubilizing Agents.The mechanism for increasing the oral bioavailability of poorly water-soluble drugs using uniform mesoporous carbon spheres as a carrier.Revisiting the rule of five on the basis of pharmacokinetic data from rat.Solid lipid nanoparticles for ocular drug delivery.Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate.Using droplet-based microfluidic technology to study the precipitation of a poorly water-soluble weakly basic drug upon a pH-shift.Acyclic cucurbit[n]uril-type molecular containers: influence of aromatic walls on their function as solubilizing excipients for insoluble drugs.Enhanced effect and mechanism of water-in-oil microemulsion as an oral delivery system of hydroxysafflor yellow AAcyclic cucurbit[n]uril-type molecular containers: influence of glycoluril oligomer length on their function as solubilizing agents.Synthesis of a Disulfonated Derivative of Cucurbit[7]uril and Investigations of its Ability to Solubilize Insoluble Drugs.Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex.Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in PregnancyLipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.Characterising lipid lipolysis and its implication in lipid-based formulation development.Highly efficient complexation of sanguinarine alkaloid by carboxylatopillar[6]arene: pKa shift, increased solubility and enhanced antibacterial activity.Microfabrication technologies for oral drug delivery.Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica.Computational prediction of drug solubility in lipid based formulation excipients.Controlled release tablet formulation containing natural Δ(9)-tetrahydrocannabinolMixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubilityOral formulation strategies to improve solubility of poorly water-soluble drugs.Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs.Inorganic matrices: an answer to low drug solubility problem.Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead.Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.Insights on novel particulate self-assembled drug delivery beads based on partial inclusion complexes between triglycerides and cyclodextrins.Amorphous solid dispersions: a robust platform to address bioavailability challenges.Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.Self-nanoemulsifying drug delivery system of nifedipine: impact of hydrophilic-lipophilic balance and molecular structure of mixed surfactants.Novel Nanostructured Solid Materials for Modulating Oral Drug Delivery from Solid-State Lipid-Based Drug Delivery Systems.Nanocarriers as treatment modalities for hypertension.
P2860
Q26776481-6CE227E4-F9C2-4216-ACF5-0B274B4437B9Q28071773-823DC55B-F37E-4934-BBE8-D9D22F1FC89BQ28084784-FA16757E-069F-431B-B95F-895C5D41C221Q30543782-A9DE82F3-B358-4249-B05E-3C66FF39EBD6Q30669947-49A714F9-C48C-4899-B0B5-C19EE0D16661Q30770195-69913176-2FEB-4B91-848D-BEAD20E5D680Q31060481-194C51E3-B488-45C8-8842-A0E638FAF639Q31161857-065B6E6C-6113-41AA-96B8-F01B54BF3BC8Q34024247-C7F7B65F-5E9F-492C-8EEB-BDD7ACE51369Q34116807-BC83C242-7E7A-44BA-B157-33E66FB2AC31Q34260371-ADB2ABBE-C2C8-423A-BD07-A8E7273F55CEQ34478120-F1201074-F42F-4D5F-BFAA-B961DC38CCB3Q34631587-5A7027FF-314F-4332-8624-19025D9668D2Q35071621-574F542D-5E69-40A3-A8A6-01FAF2E6F055Q35196330-07E74136-C346-43AF-962B-42B15105AC72Q35546753-7F87A66E-C147-49CB-AEF1-137D453C2D76Q35677172-64886EEA-EAC7-4894-922E-3AEBBABDB6E7Q35797203-C80B5F6B-BF2B-49FD-A963-D2EE96FAAE07Q36208560-871D900A-F21A-4203-9A65-735CBE31B199Q36331543-A23B380A-B78A-4CEC-9841-B361BB058A9BQ36405116-5BFB6BBB-0FE6-4BFC-AD46-6E175015C655Q36501907-0468828C-2FB3-4976-AD03-BF17420F0779Q37021478-3B92ABA2-684A-4E49-A79B-21A62223A1AEQ37248489-47811A33-1F8B-4BAA-B9AC-7993C58E734FQ37254914-A687BD3F-AE9C-4B60-9B66-FF046E0B2AFEQ37345633-625012C8-DEA1-4B43-B007-0D58ED94BCECQ37397648-F326D3D6-67B3-4A4D-8512-3735E643BE34Q37729847-8ED11002-7F0B-4758-8677-5BFBD9B03D08Q37910262-271DAFD5-09E4-4EC8-A0B7-0A146978AB5DQ37965173-D37541B1-7FC3-4DD6-9EDA-14F14E82F2E0Q38051672-088668C9-2FF2-49BB-B747-E8D211287745Q38115195-B378F7FF-3A56-464E-BCAF-F9E443B51F60Q38199539-922929AC-F95C-4193-9881-DA9ED746BF30Q38199540-A8DC6108-A448-4D62-9875-2AB92CC98E5AQ38246043-059F5D06-3F84-47BC-AA9A-9160B97D550AQ38358879-0C9BE2DD-162D-4063-9756-71FED6F22248Q38383531-338CE0F4-9EC9-4E36-A071-94A28D7EBBB0Q38555107-83509DD7-727C-4787-8F46-327722687E34Q38583850-1B199D1A-A8D9-4A0E-B0D9-4A26166D27DBQ38760963-59C09C15-0EC7-496B-A351-04B5E2491EB5
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Oral lipid-based formulations.
@en
type
label
Oral lipid-based formulations.
@en
prefLabel
Oral lipid-based formulations.
@en
P1476
Oral lipid-based formulations.
@en
P2093
David J Hauss
P304
P356
10.1016/J.ADDR.2007.05.006
P407
P577
2007-05-26T00:00:00Z